CorMatrix Cardiovascular has CE marked its extracellular matrix (ECM) biomaterial for sale in Europe. The CorMatrix ECM is used to repair heart structures during open heart surgery. The biomaterial is sutured onto the heart tissue and serves as a scaffold; over time, cells can infiltrate and replace the ECM with native tissue. According to Atlanta, Georgia-based CorMatrix, the ECM works differently to similar materials as it allows for the repair of damaged tissue without leaving permanent synthetic or foreign materials in the body, which can lead to unwanted effects. The technology has been commercially available in the US since 2006 and has been used in approximately 20,000 cardiac surgery procedures.
CorMatrix CE marks CorMatrix biomaterial
CorMatrix Cardiovascular has CE marked its extracellular matrix (ECM) biomaterial for sale in Europe. The CorMatrix ECM is used to repair heart structures during open heart surgery. The biomaterial is sutured onto the heart tissue and serves as a scaffold; over time, cells can infiltrate and replace the ECM with native tissue. According to Atlanta, Georgia-based CorMatrix, the ECM works differently to similar materials as it allows for the repair of damaged tissue without leaving permanent synthetic or foreign materials in the body, which can lead to unwanted effects. The technology has been commercially available in the US since 2006 and has been used in approximately 20,000 cardiac surgery procedures.
More from Archive
• By
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
• By
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
• By
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
More from Medtech Insight
• By
The Development Bank of Wales and London-based Parkwalk Advisors led an investment round of £5m, almost doubling Ceryx Medical's total investment to date.
• By
SS Innovations reported its first SSi Mantra 3 robotic cardiac surgery in South America as it prepares to file for US FDA de novo clearance and a CE mark. The firm aims to challenge Intuitive Surgical with a lower-cost, flexible system targeting US and European markets.
• By
Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.